- Home
- PLX vs LUCD Comparison
PLX vs LUCD Comparison
Compare PLX & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- LUCD
- Stock Information
- Founded
- PLX 1993
- LUCD 2018
- Country
- PLX United States
- LUCD United States
- Employees
- PLX N/A
- LUCD N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PLX Health Care
- LUCD Health Care
- Exchange
- PLX Nasdaq
- LUCD Nasdaq
- Market Cap
- PLX 127.4M
- LUCD 105.0M
- IPO Year
- PLX 1998
- LUCD 2021
- Fundamental
- Price
- PLX $1.91
- LUCD $1.06
- Analyst Decision
- PLX Strong Buy
- LUCD Strong Buy
- Analyst Count
- PLX 1
- LUCD 5
- Target Price
- PLX $15.00
- LUCD $3.65
- AVG Volume (30 Days)
- PLX 705.4K
- LUCD 1.6M
- Earning Date
- PLX 11-13-2025
- LUCD 11-12-2025
- Dividend Yield
- PLX N/A
- LUCD N/A
- EPS Growth
- PLX N/A
- LUCD N/A
- EPS
- PLX 0.08
- LUCD N/A
- Revenue
- PLX $61,948,000.00
- LUCD $4,360,000.00
- Revenue This Year
- PLX $14.53
- LUCD $22.80
- Revenue Next Year
- PLX $75.77
- LUCD $221.19
- P/E Ratio
- PLX $24.60
- LUCD N/A
- Revenue Growth
- PLX 62.79
- LUCD 14.74
- 52 Week Low
- PLX $0.99
- LUCD $0.73
- 52 Week High
- PLX $3.10
- LUCD $1.80
- Technical
- Relative Strength Index (RSI)
- PLX 70.20
- LUCD 44.69
- Support Level
- PLX $1.52
- LUCD $1.01
- Resistance Level
- PLX $1.69
- LUCD $1.09
- Average True Range (ATR)
- PLX 0.08
- LUCD 0.10
- MACD
- PLX 0.03
- LUCD -0.03
- Stochastic Oscillator
- PLX 91.67
- LUCD 9.43
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.